Live attenuated virus |
MV-014-212 A live attenuated vaccine that expresses the spike protein of SARS-CoV-2 |
1 |
Intranasal |
Phase 1 |
Meissa Vaccines, Inc. |
Live attenuated virus
|
COVI-VAC |
1-2 |
Intranasal |
Phase 3 |
Codagenix and Serum Institute of India |
Inactivated virus
|
CoronaVac Inactivated SARSCoV-2 vaccine |
2 |
Intramuscular |
Phase 4 |
Sinovac Research and Development Co., Ltd |
Inactivated virus
|
Inactivated SARSCoV-2 vaccine (Vero cell) |
2 |
Intramuscular |
Phase 4 |
Sinopharm, China National Biotec Group Co and Wuhan Institute of Biological Products |
Protein subunit
|
CoV2-OGEN1, protein based vaccine |
1-2 |
Oral |
Phase 1 |
USSF/Vaxform |
Protein subunit
|
RBD + AgnHB |
3 |
Intranasal |
Phase 1/2 |
Center for Genetic Engineering and Biotechnology (CIGB) |
Protein subunit
|
Full length recombinant SARSCoV-2 glycoprotein nanoparticle vaccine adjuvanted with Matrix M |
2 |
Intramuscular |
Phase 3 |
Novavax |
Protein subunit
|
MVC-COV1901 (Spike-2P protein + adjuvant CpG 1018) MVC-COV1901 (Beta) |
2 |
Intramuscular |
Phase 4 |
Medigen Vaccine Biologics, Dynavax and National Institute of Allergy and Infectious Diseases (NIAID) |
Virus like particle
|
Receptor Binding Domain (RBD) SARS-CoV-2 HbsAg VLP vaccine |
2 |
Intramuscular |
Phase 1/2 |
Serum Institute of India, Accelagen Pty and SpyBiotech |
Virus like particle
|
Coronavirus-like particle COVID-19 (CoVLP) |
2 |
Intramuscular |
Phase 3 |
Medicago Inc. |
RNA based vaccine
|
Comirnaty BNT162b2 (3 LNP - mRNAs) |
2 |
Intramuscular |
Phase 4 |
Pfizer/BioNTech and Fosun Pharma |
RNA based vaccine
|
mRNA-1273 Spikevax |
2 |
Intramuscular |
Phase 4 |
Moderna and National Institute of Allergy and Infectious Diseases (NIAID) |
DNA based vaccine
|
BacTLR-Spike oral DNA vaccine |
1 |
Oral |
Phase 1 |
Symvivo Corporation |
DNA based vaccine
|
AG0301-COVID19 |
2 |
Intramuscular |
Phase 2/3 |
AnGes, Takara Bio and Osaka University |
DNA based vaccine
|
INO-4800 + eletroporation |
2 |
Intradermal |
Phase 3 |
Inovio Pharmaceuticals, International Vaccine Institute and Advaccine (Suzhou) |
Viral vector (replicating)
|
rVSV-SARS-CoV-2-S vaccine |
1 |
Intramuscular |
Phase 2/3 |
Israel Institute for Biological Research |
Viral vector (replicating)
|
Intranasal flubased-RBD |
2 |
Intranasal |
Phase 3 |
University of Hong Kong, Xiamen University and Beijing Wantai Biological Pharmacy |
Viral vector (nonreplicating)
|
PIV5 vector that encodes the SARSCoV-2 spike protein |
1 |
Intranasal |
Phase 1 |
CyanVac LLC |
Viral vector (nonreplicating)
|
VXA-CoV2-1 Ad5 adjuvanted oral vaccine platform |
2 |
Oral |
Phase 2 |
Vaxart |
Viral vector (nonreplicating)
|
BBV154, Adenoviral vector COVID-19 vaccine |
1 |
Intranasal |
Phase 3 |
Bharat Biotech International Limited |
Viral vector (nonreplicating)
|
Covishield ChAdOx1-S (AZD1222) |
1-2 |
Intramuscular |
Phase 4 |
AstraZeneca and University of Oxford |
Viral vector (non-replicating)
|
Ad26.COV2.S |
1-2 |
Intramuscular |
Phase 4 |
Janssen Pharmaceutical Johnson & Johnson |
Viral vector (non-replicating)
|
Recombinant novel coronavirus vaccine (Adenovirus type 5 vector) |
1 |
Intramuscular |
Phase 4 |
CanSino Biological Inc./Beijing Institute of Biotechnology |